The Memorial Sloan-Kettering Cancer Center (MSKCC) recommendations on prostate cancer screening were developed in response to three limitations of previous screening guidelines: insufficient evidence-base, failure to link screening with treatment, and lack of risk stratification.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The objective of the recommendations is to provide a schema for prostate cancer screening that maximizes the benefits, in terms of reduction in prostate cancer-specific mortality, and minimizes the harms, in terms of overdiagnosis and overtreatment. We recommend the following schema for men choosing to be screened following informed decision-making. Starting at age 45, PSA without DRE. If PSA ≥ 3 ng / mL: consider prostate biopsy; PSA ≥ 1 but < 3 ng / mL: return for PSA testing every 2 - 4 years; PSA < 1 ng / mL: return for PSA testing at 6 - 10 years. PSA testing should end at age 60 for men with PSA ≤ 1 ng/ mL; at 70, unless a man is very healthy and has a higher than average PSA; at 75 for all men. The decision to biopsy a man with a PSA > 3 ng / mL should be based on a variety of factors including repeat blood draw for confirmatory testing of the PSA level, DRE results, and work-up for benign disease. Additional reflex tests in blood such as a free-to-total PSA ratio, the Prostate Health Index, or 4Kscore, or urinary testing of PCA3, can also be informative in some patients. The best evidence suggests that more restricted indication for prostate biopsy and a more focused approach to pursue screening in men at highest risk of lethal cancer would retain most of the mortality benefits of aggressive screening schema, while importantly reducing harms from overdetection and overtreatment.
Urology. 2016 Feb 02 [Epub ahead of print]
Andrew J Vickers, James A Eastham, Peter T Scardino, Hans Lilja
Memorial Sloan-Kettering Cancer Center. Memorial Sloan-Kettering Cancer Center. , Memorial Sloan-Kettering Cancer Center. , Memorial Sloan-Kettering Cancer Center.